Home
NewsNewsThe ESHRE 2025 Annual Meeting in Paris highlighted advancements in reproductive medicine, covering the psychological effects of pregnancy loss, AI's role in enhancing IVF predictions, and the resilience of 2S/LGBTQIA+ couples. It also introduced the T'easy AI platform for sperm detection and discussed preimplantation genetic testing benefits for older women.
The 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Paris, France, has unveiled significant advances across reproductive medicine, from artificial intelligence applications to psychological support needs, offering new hope and enhanced treatment approaches for fertility patients worldwide.
A comprehensive prospective study led by Astrid Marie Kolte from Copenhagen University Hospitals and Hvidovre Hospital in Denmark has illuminated the substantial psychological burden of pregnancy loss on both women and their partners. The four-year study tracked over 2,000 women and 1,200 partners, assessing mental health symptoms within 2–8 weeks following a pregnancy loss.
The findings reveal concerning levels of psychological distress among women experiencing pregnancy loss: 49.4% reported elevated stress, 24.1% experienced moderate-to-severe anxiety, and 12.2% met criteria for moderate-to-severe depression. Partners faced significant challenges as well, with 23.6% reporting stress, 8.3% experiencing anxiety, and 3.8% developing depression.
The research identified critical risk factors, including prior pregnancy losses and insufficient primary treatment, both strongly linked to worse mental health outcomes. Conversely, having living children correlated with lower distress rates across all measures. This study stands among the few to examine both members of couples, revealing that "pregnancy loss is not only a clinical event but a deeply emotional one, with lasting implications for both individuals.
Researchers have demonstrated that machine learning significantly outperforms traditional age-based methods in predicting IVF pregnancy success. The international, multicentre study analysed 3,852 first autologous IVF cycles performed between 2018-2023 across six fertility centres in two countries.
The AI model incorporated multiple clinical variables, including maternal and paternal age, anti-Müllerian hormone levels, antral follicle count, sperm origin and type, and history of past failed cycles. The system achieved superior performance compared to age-only models, with an area under the curve score of 0.731 versus 0.695 and improved accuracy of 67.5% versus 65.3%.
Particularly impressive were the model's predictions at extremes: over 86% accuracy for women with less than 20% chance of pregnancy and nearly 78% accuracy for those with greater than 80% chance. While maternal age remained the top predictor for first transfers, subsequent transfers showed ovarian reserve markers becoming more influential.
Marie-Caroline Compans from the Sexual and Reproductive Health and Rights Unit at Institut national d'études démographiques in Aubervilliers, France, presented research highlighting significant challenges in accurately measuring miscarriage prevalence. The comprehensive study drew on 13,632,246 medical records for pregnancies, FECOND study survey data from 2010-11 representing 7,196 pregnancies, and 50 in-depth interviews about miscarriage experiences.
Hospital-managed miscarriages declined from 6.9% of clinically recognised pregnancies in 2009 to 5.1% in 2023, according to the French National Health Data System. Including primary care data, rates ranged from 9.9% in 2013 to 8.9% in 2023, still considerably lower than the 14.0% miscarriage rate reported in the FECOND national survey.
This discrepancy suggests many miscarriages remain unreported in medical records, particularly those managed outside hospitals. The research confirmed maternal age and previous miscarriages as major risk factors while finding no strong links between miscarriage and socio-economic status.
A retrospective cohort study examining 2,385 women who underwent their first two single embryo frozen embryo transfers (FETs) between 2017–2021 provides reassuring evidence for fertility patients. The research demonstrated that prior failed FET, whether due to biochemical pregnancy loss, clinical pregnancy loss, or implantation failure, does not increase the risk of another pregnancy loss in subsequent FET.
Second FET outcomes were statistically similar across all groups regardless of first transfer results. Live birth rates in the second FET showed no significant difference across groups, with results remaining consistent after accounting for age, embryo quality, BMI, endometrial thickness, and hormonal levels.
Research examining 345 couples (80 2S/LGBTQIA+ and 265 mixed-sex/gender) recruited from Canada and the USA between November 2019-April 2024 revealed important insights into fertility care experiences for diverse populations. While 20% of medically assisted reproduction-seeking couples identify as 2S/LGBTQIA+, fertility care remains rooted in a medicalised, cisgender framework.
Mixed-sex/gender couples demonstrated higher depressive symptoms (F[1, 205.347]=7.123; p=0.008; d=0.34), while 2S/LGBTQIA+ couples reported greater relationship satisfaction (F[1, 212.442]=8.288; p=0.004; d=–0.39) and more frequent use of dyadic coping strategies (F[1, 206.457]=5.929; p=0.016; d=–0.35).
Despite facing barriers including heteronormativity, financial strain, and microaggressions from healthcare providers, 2S/LGBTQIA+ couples showed resilience through strong relational bonds and robust social support networks.
Researchers from UZ Brussel, Belgium, in collaboration with Robovision AI, Ghent, Belgium, introduced T'easy, an innovative AI-driven platform revolutionising sperm identification in testicular tissue samples. The system was trained on 5,373 annotated images and more than 13,000 labelled spermatozoa.
In initial testing, T'easy achieved 95.0% recall and 94.8% precision. In clinical samples, the system identified over 98% of sperm cells with fewer false positives and negatives than human operators, completing analysis in just 10 minutes compared to 24 minutes required by experienced embryologists.
A large-scale retrospective study from Igenomix Vitrolife Group, Valencia, Spain, analysed 7,795 endometrial biopsies, investigating Lactobacillus species presence and their relationship to 26 potential reproductive tract pathogens. The research revealed significant variations between species.
Lactobacillus crispatus was associated with lower pathogen prevalence at 11.9%, while Lactobacillus gasseri showed the opposite trend, with nearly half (45.8%) of samples testing positive for at least one pathogen. Lactobacillus iners and Lactobacillus jensenii showed intermediate pathogen rates of 28.7% and 24.2%, respectively.
A multinational study across private fertility networks analysed 4,763 patients aged ≥35 years undergoing their first IVF/intracytoplasmic sperm injection cycle. Using propensity score matching, researchers compared 1,440 patients who underwent preimplantation genetic testing for aneuploidy (PGT-A) with 1,440 who did not.
While cumulative live birth rates remained comparable (30.1% with PGT-A versus 32.4% without), the live birth rate per embryo transfer was significantly higher in the PGT-A group (44.2% versus 29.1%; adjusted odds ratio: 2.15; 95% CI: 1.78–2.61). Crucially, PGT-A provided significant time-to-pregnancy advantages specifically for women aged ≥39, with notably shorter time to live birth (adjusted hazard ratio: 2.53; 95% CI: 1.56–4.12).
These ESHRE 2025 findings collectively represent substantial progress in reproductive medicine, offering enhanced treatment precision, improved patient support frameworks, and technological innovations that promise to transform fertility care delivery worldwide.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
The Minnesota bill for infertility treatments mandates comprehensive insurance coverage for diagnosis, IVF, and fertility preservation across public and private health plans. Set for implementation in 2027, the legislation expands access, modernises infertility definitions, and ensures cost-sharing protections to make reproductive healthcare more equitable.
